PTC Therapeutics, Inc.
PTCT
$50.57
$1.653.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.76B | 1.77B | 806.78M | 900.66M | 900.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.76B | 1.77B | 806.78M | 900.66M | 900.45M |
| Cost of Revenue | 559.56M | 582.84M | 591.88M | 601.30M | 602.74M |
| Gross Profit | 1.21B | 1.19B | 214.90M | 299.37M | 297.71M |
| SG&A Expenses | 324.36M | 308.60M | 300.91M | 292.52M | 299.95M |
| Depreciation & Amortization | 14.20M | 13.01M | 60.74M | 134.61M | 190.22M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 898.12M | 904.45M | 953.53M | 1.03B | 1.09B |
| Operating Income | 866.81M | 868.31M | -146.75M | -127.76M | -192.45M |
| Income Before Tax | 666.09M | 651.41M | -363.12M | -425.47M | -494.07M |
| Income Tax Expenses | 36.91M | 56.56M | 176.00K | 27.73M | -14.55M |
| Earnings from Continuing Operations | 629.17 | 594.84 | -363.30 | -453.20 | -479.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 629.17M | 594.84M | -363.30M | -453.20M | -479.52M |
| EBIT | 866.81M | 868.31M | -146.75M | -127.76M | -192.45M |
| EBITDA | 894.86M | 895.80M | -71.08M | 21.85M | 12.72M |
| EPS Basic | 8.02 | 7.56 | -4.73 | -5.94 | -6.32 |
| Normalized Basic EPS | 6.42 | 6.38 | -1.78 | -2.33 | -2.85 |
| EPS Diluted | 6.97 | 6.51 | -4.73 | -5.94 | -6.32 |
| Normalized Diluted EPS | 5.71 | 5.66 | -1.78 | -2.33 | -2.85 |
| Average Basic Shares Outstanding | 310.39M | 308.97M | 307.35M | 305.64M | 304.09M |
| Average Diluted Shares Outstanding | 318.66M | 317.24M | 307.35M | 305.64M | 304.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |